NDAINTRAVENOUSPOWDER
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
RYTELO (imetelstat sodium) by Geron is 12. Approved for more red blood cell units over 8 weeks. First approved in 2024.
Drug data last refreshed 20h ago
Mechanism of Action
12.1. Mechanism of Action Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the template region of the RNA component of human telomerase (hTR), inhibits telomerase enzymatic activity and prevents telomere binding. Increased telomerase activity and human telomerase reverse…
Indications (1)
Clinical Trials (1)
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Started Oct 2012
80 enrolled
Primary MyelofibrosisSecondary MyelofibrosisMyeloid Malignancies
Worked on RYTELO at Geron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.